Basilea Pharmaceutica AG : Basilea receives request to place repayment of CHF 48 million from capital contribution reserve on

Basilea Pharmaceutica AG : Basilea receives request to place repayment of CHF
  48 million from capital contribution reserve on the agenda of the ordinary
                       general meeting of shareholders

Basilea Pharmaceutica AG / Basilea receives request to place repayment of CHF
48 million from capital contribution reserve on the agenda of the ordinary
general meeting of shareholders . Processed and transmitted by Thomson Reuters
ONE. The issuer is solely responsible for the content of this announcement.

Basel, Switzerland, February 22, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
has received a request from one of its shareholders, HBM Healthcare
Investments (Cayman) Ltd., which holds more than 20% of Basilea's shares, to
place the repayment of CHF 5.00 per registered share from the company's
capital contribution reserve on the agenda of Basilea's upcoming ordinary
general meeting of shareholders, for a total of approximately CHF48 million.

Basilea's board of directors will carefully evaluate the request.

Basilea's ordinary general meeting of shareholders is scheduled for April 9,
2013. The deadline for registration in the share register to vote at the
ordinary general meeting of shareholders is March28, 2013.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed
on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research
and development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd., the company focuses on innovative pharmaceutical products
in the therapeutic areas of bacterial infections, fungal infections and
oncology, targeting the medical challenge of rising resistance and
non-response to current treatment options.

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance or achievements of Basilea Pharmaceutica Ltd. to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise.

For further information, please contact:

Media Relations             Investor Relations
Peer Nils Schröder, Ph.D.   Barbara Zink, Ph.D., MBA
Head Public Relations &     Head Corporate Development
Corporate Communications
+41 61 606 1102             +41 61 606 1233
media_relations@basilea.com investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

Press release (PDF)

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
HUG#1680620

--- End of Message ---

Basilea Pharmaceutica AG
Grenzacherstrasse 487
P.O Box Basel Switzerland

Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München;
 
Press spacebar to pause and continue. Press esc to stop.